Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1051-1058

  Schultz, Iman J ^a   De Kok, Jacques B ^a   Witjes, J Alfred ^a   Babjuk, Marko ^b   Willems, Johannes L ^a   Wester, Kenneth ^c   Swinkels, Dorine W ^a   Tjalsma, Harold ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Real time Q PCR; Recurrence; SELDI TOF; Ta tumors; Urothelial cell carcinoma

Indexed keywords

MESSENGER RNA; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEMALE; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINARY TRACT CARCINOMA; UROTHELIAL CELL CARCINOMA;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENOMICS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROTEOMICS; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 34247116622     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Allard P, Bernard P, Fradet Y and Tetu B: The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81: 692-698, 1998.
2. Kiemeney LA, Witjes JA, Verbeek AL, Heijbroek RP and Debruyne FM: The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 67: 806-812, 1993.
3. Abel PD, Hall RR and Williams G: Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br J Urol 62: 235-239, 1988.
4. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD and Hawkins IR: Superficial bladder cancer: progression and recurrence. J Urol 130: 1083-1086, 1983.
5. Zieger K, Wolf H, Olsen PR and Hojgaard K: Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU Int 85: 824-828, 2000.
6. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C and Johansson SL: Recurrence and progression in low grade papillary urothelial tumors. J Urol 162: 702-707, 1999.
7. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O and Ogreid P: Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 169: 1291-1294, 2003.
8. Tosoni I, Wagner U, Sauter G, Egloff M, Knonagel H, Alund G, Bannwart F, Mihatsch MJ, Gasser TC and Maurer R: Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 85: 48-53, 2000.
9. Schultz IJ, Witjes JA, Swinkels DW and de Kok JB: Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on survivin. Clin Chim Acta 368: 20-32, 2006.
10. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H and Orntoft TF: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96, 2003.
11. Ramos D, Navarro S, Villamon R, Gil-Salom M and Llombart-Bosch A: Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer 97: 1876-1883, 2003.
12. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC and van der Kwast TH: Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198: 245-251, 2002.
13. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A and Navone R: Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 95: 784-790, 2002.
14. Toma V, Hauri D, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Gasser TC, Sauter G and Roth J: Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 155: 1427-1432, 1999.
15. Weikert S, Christoph F, Schrader M, Krause H, Miller K and Muller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116: 100-104, 2005.
16. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems JL, Swinkels DW, Witjes JA, de Kok JB and Malmstrom PU: Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer 119: 1915-1919, 2006.
17. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems JL, Swinkels DW, Witjes JA, Malmstrom PU and de Kok JB: Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol, 2006.
18. Mostofi FK, Sobin LH and Torloni H: Histologic typing of urinary bladders. In: Anonymous. International histological classification of tumors. Geneva: World Health Organisation, p. 36, 1973.
19. Spiessl B, Beahrs OH, Hermanek P, Hutter RV, Scheibe O and Sobin LH: Anonymous TNM atlas. In: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. 3rd ed., 2nd revision. Springer-Verlag, Berlin, pp. 274-279, 1992.
20. Jorgensen CS, Jagd M, Sorensen BK, McGuire J, Barkholt V, Hojrup P and Houen G: Efficacy and compatibility with mass spectrometry of methods for elution of proteins from sodium dodecyl sulfate-polyacrylamide gels and polyvinyldifluoride membranes. Anal Biochem 330: 87-97, 2004.
21. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW and Span PN: Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85: 154-159, 2005.
22. Man TK, Li Y, Dang TA, Shen J, Perlaky L and Lau CC: Optimising the use of TRIzol-extracted proteins in surface enhanced laser desorption / ionization (SELDI) analysis. Proteome Sci 4: 3, 2006.
23. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, Rasmussen HH, Orntoft TF, Hein B, Wolf H and Celis A: Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res 59: 3003-3009, 1999.
24. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y and Yoshiki T: Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 50: 857-866, 2004.
25. Moreira JM, Gromov P and Celis JE: Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 3: 410-419, 2004.
26. Ohlsson G, Moreira JM, Gromov P, Sauter G and Celis JE: Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 4: 570-581, 2005.
27. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, Mueller GA, Kuczyk M and Mueller CA: Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6: 697-708, 2006.
28. Celis JE, Celis P, Palsdottir H, Ostergaard M, Gromov P, Primdahl H, Orntoft TF, Wolf H, Celis A and Gromova I: Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 1: 269-279, 2002.
29. Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999.
30. Hilmy M, Bartlett JM, Underwood MA and McMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 92: 625-627, 2005.
31. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC and Zwarthoff EC: Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21: 1912-1921, 2003.